The FDA is taking steps that may lead to the expansion of testosterone therapy to treat low libido in men. This potential expansion could apply to men with idiopathic hypogonadism, a condition in which the testes do not produce enough testosterone. The development appears to be separate from recent approval of a libido-boosting pill for postmenopausal women.